Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 in myelofibrosis after prior JAK inhibitor failure
2018-001671-21Phase 2Unknown
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of navtemadlin in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Kartos Therapeutics. Primary endpoint: Spleen volume reduction response at Week 24. Status: unknown.
02
Drugs
navtemadlin
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2018-001671-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001671-21.